Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 54.07B | 45.81B | 44.35B | 37.42B | 26.62B |
| Gross Profit | 43.87B | 37.77B | 31.96B | 24.98B | 21.32B |
| EBITDA | 15.44B | 13.91B | 9.09B | 5.11B | 8.08B |
| Net Income | 7.04B | 5.96B | 3.29B | 112.00M | 3.20B |
Balance Sheet | |||||
| Total Assets | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B |
| Cash, Cash Equivalents and Short-Term Investments | 5.53B | 5.86B | 6.41B | 6.40B | 7.99B |
| Total Debt | 30.11B | 28.62B | 29.23B | 30.78B | 20.38B |
| Total Liabilities | 63.16B | 61.95B | 59.42B | 66.08B | 51.09B |
| Stockholders Equity | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
Cash Flow | |||||
| Free Cash Flow | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B |
| Operating Cash Flow | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B |
| Investing Cash Flow | -7.98B | -4.06B | -2.96B | -11.06B | -285.00M |
| Financing Cash Flow | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Risk Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | £161.83B | 26.15 | 19.90% | 2.55% | 13.74% | 21.45% | |
76 Outperform | £9.60B | 30.31 | 7.78% | 3.19% | 1.85% | 51.77% | |
73 Outperform | £56.67B | 18.16 | 22.52% | 3.28% | 2.57% | -30.13% | |
68 Neutral | £4.35B | 15.72 | 15.79% | 2.92% | 5.83% | 83.35% | |
50 Neutral | AU$2.51B | 3.43 | -57.47% | 2.67% | 36.73% | 13.67% | |
| ― | $42.92B | 4.11 | 13.12% | 8.48% | ― | ― | |
67 Neutral | £32.65B | 23.01 | 8.80% | 1.89% | -0.61% | 39.00% |
AstraZeneca Corporate Events
AstraZeneca’s CARES Phase III clinical program for anselamimab in light chain amyloidosis did not achieve statistical significance for the primary endpoint in the overall patient population. However, anselamimab showed clinically meaningful improvements in survival and cardiovascular hospitalization in a prespecified subgroup of patients, indicating potential to address a critical treatment gap. The investigational drug was well tolerated, and further evaluation is ongoing to assess its efficacy and safety, with plans to share data with global health authorities.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced positive results from its BaxHTN Phase III trial, where its drug Baxdrostat significantly reduced systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension. This breakthrough offers a potential new treatment approach targeting aldosterone dysregulation, addressing a critical unmet need in hypertension management and potentially enhancing AstraZeneca’s position in the cardiovascular market.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi has been approved by the European Union as the first perioperative immunotherapy for muscle-invasive bladder cancer, based on the NIAGARA Phase III trial results. This approval is expected to transform the standard of care in Europe, offering a significant reduction in disease recurrence and extending survival rates, thereby setting a new benchmark for treatment in this area.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca PLC has announced that as of 30 June 2025, its issued share capital with voting rights totals 1,550,670,668 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to calculate their interests in compliance with the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how stakeholders manage their shareholdings.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca, in collaboration with Daiichi Sankyo, has announced the accelerated approval of Datroway (datopotamab deruxtecan) in the US for the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously undergone EGFR-directed therapy and platinum-based chemotherapy. This approval marks the first TROP2-directed therapy for lung cancer in the US, offering a new treatment option for patients with limited alternatives. The approval is based on promising results from the TROPION-Lung05 and TROPION-Lung01 trials, demonstrating a significant objective response rate and duration of response. The introduction of Datroway is expected to strengthen AstraZeneca’s position in the oncology market, providing a novel option for patients with advanced disease and potentially expanding its use in other cancer types.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has received approval from the European Union for a fixed-duration regimen of its drug Calquence, in combination with venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This approval is based on positive results from the AMPLIFY Phase III trial, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval provides a new all-oral treatment option that may help minimize long-term side effects and improve adherence, potentially impacting AstraZeneca’s market position in the oncology sector.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £190.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced that as of 31 May 2025, its issued share capital with voting rights consists of 1,550,657,962 ordinary shares. This figure is significant for shareholders as it serves as the denominator for calculating their interests under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi has been recommended for approval by the CHMP in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer. The recommendation is based on the NIAGARA Phase III trial, which showed significant reductions in disease recurrence and death risk compared to neoadjuvant chemotherapy alone. This approval could transform treatment approaches in Europe, offering a new standard of care for patients with resectable muscle-invasive bladder cancer.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi has been recommended for approval in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC), based on the NIAGARA Phase III trial results. The trial demonstrated significant reductions in the risk of disease progression and death, supporting Imfinzi’s potential to become a new standard of care in Europe, offering a much-needed treatment option for MIBC patients and potentially transforming the treatment landscape.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced the vesting of ordinary shares to CEO Pascal Soriot under the AstraZeneca Performance Share Plan. The award, granted in 2020, vested after a three-year performance period and a two-year holding period, resulting in 97% of the award vesting. This transaction reflects AstraZeneca’s commitment to rewarding its leadership based on performance, potentially impacting the company’s executive compensation strategy and stakeholder perceptions.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £14500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has completed the acquisition of EsoBiotec, a biotechnology company known for its innovative in vivo cell therapies, particularly the Engineered NanoBody Lentiviral (ENaBL) platform. This acquisition, valued at up to $1 billion, positions AstraZeneca to enhance its cell therapy capabilities, potentially transforming cancer treatment by enabling quicker and more accessible therapies. The acquisition aligns with AstraZeneca’s strategic focus on oncology and immune-mediated diseases, aiming to redefine cancer care and address unmet needs in chronic diseases.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced positive results from its POTOMAC Phase III trial, where the Imfinzi regimen showed a significant improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer. This advancement could potentially enhance treatment options for early-stage bladder cancer, aligning with AstraZeneca’s strategy to bring novel therapies to patients where long-term benefits are most achievable. The safety profile of Imfinzi combined with BCG therapy was consistent with known profiles, and no new safety concerns were identified. These findings will be shared with global regulatory authorities, potentially impacting AstraZeneca’s market positioning and offering new hope for stakeholders involved in bladder cancer treatment.
AstraZeneca and Daiichi Sankyo announced positive results from the DESTINY-Breast11 Phase III trial, showing that Enhertu followed by THP significantly improves pathologic complete response rates in high-risk HER2-positive early-stage breast cancer patients compared to the standard of care. This trial marks the first Phase III success for Enhertu in early breast cancer and suggests a potential shift in treatment paradigms, offering a promising new approach that could improve patient outcomes and challenge existing standards.
AstraZeneca’s Calquence, in combination with bendamustine and rituximab, has been approved by the European Union for first-line treatment of adult patients with mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval, based on the ECHO Phase III trial results, marks Calquence as the first and only BTK inhibitor approved for this indication in the EU, offering a significant improvement in progression-free survival and providing a new treatment option for patients with this aggressive form of non-Hodgkin lymphoma.
AstraZeneca announced that its fixed-dose triple-combination therapy, Breztri Aerosphere, met all primary endpoints in the Phase III KALOS and LOGOS trials for patients with uncontrolled asthma. The trials demonstrated significant improvements in lung function compared to dual-combination therapies, highlighting Breztri’s potential to improve asthma treatment. These results build on Breztri’s established efficacy in treating COPD and could expand its use to a broader patient population, enhancing AstraZeneca’s position in the respiratory care market.
AstraZeneca announced that Karen Knudsen, a Non-Executive Director, purchased 1,400 American Depositary Shares (ADSs) of the company on April 30, 2025. This transaction, priced at $71.655 per ADS, reflects potential confidence in the company’s market position and future performance, possibly impacting stakeholder perceptions positively.
AstraZeneca has announced that as of April 30, 2025, its issued share capital with voting rights consists of 1,550,638,452 ordinary shares, with no shares held in Treasury. This total number of voting rights is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for a fixed-duration regimen of its drug Calquence, in combination with venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) in the EU. This recommendation is based on the AMPLIFY Phase III trial results, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval could position Calquence as a leading treatment option in Europe, offering patients a more flexible and potentially safer treatment regimen.
AstraZeneca has decided to discontinue the CAPItello-280 Phase III trial for Truqap in combination with docetaxel and androgen-deprivation therapy in patients with metastatic castration-resistant prostate cancer. This decision follows the Independent Data Monitoring Committee’s recommendation after an interim analysis indicated that the trial was unlikely to meet its primary endpoints of radiographic progression-free survival and overall survival. The company will collaborate with investigators for patient follow-up and utilize the trial data for ongoing research, highlighting the continued challenges and unmet needs in treating this aggressive form of prostate cancer.
AstraZeneca reported strong financial results for Q1 2025, with a 10% increase in total revenue driven by growth in oncology and biopharmaceuticals. The company achieved five positive Phase III study readouts and 13 approvals in major regions, reinforcing its strong growth momentum and positioning it well towards its 2030 revenue ambition. Despite ongoing investigations in China, AstraZeneca continues to expand its operations, including acquiring FibroGen China and EsoBiotec, enhancing its capabilities in cell therapies.
AstraZeneca, in collaboration with Daiichi Sankyo, announced positive interim results from the DESTINY-Breast09 Phase III trial, demonstrating that Enhertu combined with pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer compared to the current standard of care. This breakthrough marks a significant advancement in first-line treatment options for this aggressive cancer type, potentially delaying disease progression and offering a new hope for patients who typically face a poor prognosis.